









Markets
/
Stocks
/
nasdaq-klrs
/

Kalaris Therapeutics Inc

KLRS



View Detailed Chart

10.060USD

+0.930+10.19%

Close 12/22, 16:00（ET）Quotes delayed by 15 min

188.15MMarket Cap

LossP/E TTM



Kalaris Therapeutics Inc

10.060

+0.930+10.19%

Overview Company Financials Analysis

Overview

Company

Financials

Analysis

Intraday

30m

Today

+10.19%

5 Days

+13.42%

1 Month

+43.51%

6 Months

+319.17%

Year to Date

+4.14%

1 Year

+8.27%

View Detailed Chart

TradingKey Stock Score of Kalaris Therapeutics Inc

Currency: USD Updated: 2025-12-19

Key Insights

Kalaris Therapeutics Inc's fundamentals are relatively very healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 133/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 17.00.In the medium term, the stock price is expected to trend up.Despite strong stock market performance and technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Kalaris Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

133 / 404

Overall Ranking

255 / 4582

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Analyst Rating

Based on 5 analysts

Buy

Current Rating

17.000

Target Price

+175.97%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Kalaris Therapeutics Inc Highlights

StrengthsRisks

Kalaris Therapeutics, Inc., formerly AlloVir, Inc., is a clinical-stage biopharmaceutical company engaged in the development and commercialization of treatments for prevalent retinal diseases. The Company is focused on the development of TH103, a differentiated anti-vascular endothelial growth factor (VEGF) investigational therapy. TH103 is a fully humanized, recombinant fusion protein that acts against VEGF as a decoy receptor and has been specifically engineered for potentially improved VEGF inhibition and longer retention in the retina. TH103 is being evaluated in an ongoing, Phase I clinical trial for the treatment of neovascular age-related macular degeneration (nAMD), with plans to develop TH103 for additional neovascular and exudative diseases of the retina such as diabetic macular edema (DME), and retinal vein occlusion (RVO).

Fairly Valued

The company’s latest PE is -0.04, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 13.23M shares, decreasing 7.34% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 112.75K shares of this stock.